+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Antiemetic placebo: reduce adverse drug interactions between chemotherapeutic agents and antiemetic drugs in cancer patients



Antiemetic placebo: reduce adverse drug interactions between chemotherapeutic agents and antiemetic drugs in cancer patients



Medical Hypotheses 70(3): 551-555



Cancer patients receiving chemotherapy often require a wide range of drugs to manage symptoms of their cancer. The adverse drug interactions are common in the field of medical oncology. Chemotherapy-induced nausea and vomiting (CINV) continues to have a considerable effect on the physical and psychological well-being of patients with cancer, despite significant advances in antiemetic drugs since the 1990s. Fortunately, evidence-based interventions suggested that to a certain extent antiemetic effects can be achieved by use of placebo appropriately. Placebo effect can be reinforced by conferring much meaning. Thus physician can replace antiemetic drugs with reinforced meaningful antiemetic placebo to get better prevention and treatment efficacy for CINV while reduce the unnecessary adverse drug interactions induced by antiemetic drugs and chemotherapeutic agents.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 030117220

Download citation: RISBibTeXText

PMID: 17703892

DOI: 10.1016/j.mehy.2007.06.029


Related references

Cancer patients submitted to innovative chemotherapeutic agents of intermediate emetogenic potential: antiemetic prescriptions and incidence of emesis. Tumori 90(1): 103-106, 2004

Antiemetic drugs for chemotherapeutic support. Current treatment and rationale for development of newer agents. Cancer 70(4 Suppl): 1003-1006, 1992

Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Supportive Care in Cancer 23(1): 273-282, 2015

Enhancement of the antiemetic action of ondansetron by transcutaneous electrical stimulation of the p6 antiemetic point in patients having highly emetic cytotoxic drugs. British Journal of Cancer 64(5): 971-972, 1991

Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(8): 1129-1131, 2006

Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns. American Journal of Health-System Pharmacy 64(21): 2227-2236, 2007

Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy. International Journal of Clinical Pharmacy 2018, 2018

Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience 9: 567, 2015

Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein. Official Gazette of the United States Patent & Trademark Office Patents 1200(2): 1348, July 8, 1997

Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein us patent 4772459. september 20 1988. Official Gazette of the United States Patent & Trademark Office Patents 1094(3): 1495, 1988

Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report. Anticancer Research 19(4c): 3495-3502, 2000

A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. Bmc Cancer 18(1): 510, 2018

Antiemetic Efficacy of Tropisetron in Patients Failing Previous Antiemetic Therapy. Oncology 52(5): 427-431, 1995

Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy. Oncology 52(5): 427-431, 1995

Side effects of drug treatment for ovarian cancer after administration of antiemetic drugs. Ginekologia Polska 64(9): 438-442, 1993